Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Raw Materials (2016 - 2026)

Avanos Medical's Raw Materials history spans 12 years, with the latest figure at $4.1 million for Q4 2025.

  • On a quarterly basis, Raw Materials rose 41.38% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 41.38% increase, with the full-year FY2025 number at $4.1 million, up 41.38% from a year prior.
  • Raw Materials hit $4.1 million in Q4 2025 for Avanos Medical, up from $4.0 million in the prior quarter.
  • Over the last five years, Raw Materials for AVNS hit a ceiling of $57.0 million in Q1 2023 and a floor of $2.9 million in Q4 2024.
  • Historically, Raw Materials has averaged $31.5 million across 5 years, with a median of $39.2 million in 2023.
  • The widest YoY moves for Raw Materials: up 841.03% in 2025, down 91.56% in 2025.
  • Tracing AVNS's Raw Materials over 5 years: stood at $6.8 million in 2021, then skyrocketed by 439.71% to $36.7 million in 2022, then crashed by 87.47% to $4.6 million in 2023, then tumbled by 36.96% to $2.9 million in 2024, then skyrocketed by 41.38% to $4.1 million in 2025.
  • Business Quant data shows Raw Materials for AVNS at $4.1 million in Q4 2025, $4.0 million in Q3 2025, and $36.7 million in Q2 2025.